Ambroxol lozenge bioavailability - An open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy Thai volunteers

被引:9
|
作者
Rojpibulstit, M [1 ]
Kasiwong, S [1 ]
Juthong, S [1 ]
Phadoongsombat, N [1 ]
Faroongsarng, D [1 ]
机构
[1] Prince Songkla Univ, Fac Pharmaceut Sci, Songkhla, Thailand
关键词
D O I
10.2165/00044011-200323040-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. Design: Open-label, two-way crossover study. Method: Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After administration, serial blood samples were collected over a 24-hour period and the plasma concentration of ambroxol was subsequently measured using high performance liquid chromatography with ultraviolet detection after liquid-liquid extraction. Pharmacokinetic parameters were analysed by a noncompartmental pharmacokinetic model and compared between formulations using analysis of variance with a significance level of 0.05. Results: The point estimates (90% CI) of the area under the plasma concentration-time curve (AUC) and peak plasma concentration (C-max) ratios between lozenge and commercial tablet were 1.07 (0.89 to 1.28) and 1.20 (1.04 to 1.40), respectively. The point estimate (90% CI) of the difference between formulations for time to C-max was 0.40 (-0.20 to 1.00). Conclusion: The two formulations under test were not bioequivalent based on the stipulated bioequivalence criteria. The biclavailability from the ambroxol lozenge might be better, since the 90% CI of the AUC(0-infinity) fell outside the bioequivalence range, and its range was narrower. The difference in rate of absorption was not conclusive because ambroxol was delivered from the lozenge by two parallel processes, namely absorption via oral and gastrointestinal mucosa. The additional oral mucosal absorption might not only contribute more absorption but also introduce variability compared with that of tablet administration. The relative importance of oral versus gastrointestinal mucosal absorption of ambroxol from the lozenge formulation, and the clinical significance of this, requires further study.
引用
下载
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [31] A Randomized, Open-Label, Crossover Study Evaluating the Effect of Food on the Relative Bioavailability of Linagliptin in Healthy Subjects
    Graefe-Mody, Ulrike
    Giessmann, Thomas
    Ring, Arne
    Iovino, Mario
    Woerle, Hans-Juergen
    CLINICAL THERAPEUTICS, 2011, 33 (08) : 1096 - 1103
  • [32] Relative Bioavailability of Sapropterin From Intact and Dissolved Sapropterin Dihydrochloride Tablets and the Effects of Food: A Randomized, Open-Label, Crossover Study in Healthy Adults
    Musson, Donald G.
    Kramer, William G.
    Foehr, Erik D.
    Bieberdorf, Frederick A.
    Hornfeldt, Carl S.
    Kim, Sun Sook
    Dorenbaum, Alex
    CLINICAL THERAPEUTICS, 2010, 32 (02) : 338 - 346
  • [33] Relative Bioavailability of Generic and Branded Acetylcysteine Effervescent Tablets: A Single-Dose, Open-Label, Randomized-Sequence, Two-Period Crossover Study in Fasting Healthy Chinese Male Volunteers
    Liu, Yan-Mei
    Liu, Yun
    Lu, Chuan
    Jia, Jing-Ying
    Liu, Gang-Yi
    Weng, Li-Ping
    Wang, Jia-Yan
    Li, Guo-Xiu
    Wang, Wei
    Li, Shui-Jun
    Yu, Chen
    CLINICAL THERAPEUTICS, 2010, 32 (12) : 2097 - 2105
  • [34] Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers
    Atkinson, Hartley C.
    Stanescu, Ioana
    Salem, Isam I.
    Potts, Amanda L.
    Anderson, Brian J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (02) : 151 - 158
  • [35] Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers
    Hartley C. Atkinson
    Ioana Stanescu
    Isam I. Salem
    Amanda L. Potts
    Brian J. Anderson
    European Journal of Clinical Pharmacology, 2015, 71 : 151 - 158
  • [36] Bioavailability of Two Oral Formulations of a Single Dose of Levofloxacin 500 mg: An Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Volunteers
    Galan-Herrera, Juan Francisco
    Poo, Jorge Luis
    Rosales-Sanchez, Oscar
    Fuentes-Fuentes, Elvira
    Carino, Lizbeth
    Burke-Fraga, Victoria
    Namur, Salvador
    Gonzalez-de la Parra, Mario
    CLINICAL THERAPEUTICS, 2009, 31 (08) : 1796 - 1803
  • [37] AN OPEN-LABEL STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY OF SOTORASIB ADMINISTERED AS TABLETS OR AS A WATER DISPERSION IN HEALTHY SUBJECTS.
    Cardona, P.
    Spring, M.
    Purkis, J.
    Mather, O.
    Dutta, S.
    Houk, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S11 - S12
  • [38] Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects A single, randomized, two-way cross-over, open-label phase I study
    Izquierdo, Inaki
    Borja, Javier
    Rovira, Sandra
    Pelagio, Pilar
    Torres, Ferran
    Cebrecos, Jesus
    Garcia-Rafanell, Julian
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2010, 60 (01): : 36 - 41
  • [39] Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study
    Hsyu, Poe-Hirr
    Pignataro, Daniela Soriano
    Matschke, Kyle
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (04): : 373 - 381
  • [40] Comparative study on the bioequivalence of two formulations of pravastatin - Data from a crossover, randomised, open-label bioequivalence study in healthy volunteers
    Almeida, S
    Filipe, A
    Almeida, A
    Gich, I
    Antonijoan, R
    Puntes, M
    Barbanoj, M
    Caturla, MC
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2006, 56 (02): : 70 - 75